ヒトPCSK9測定ELISAキット Human PCSK9 ELISA Kit

試料中のヒトPCSK9（Proprotein convertase subtilisin/kexin type 9）を、サンドイッチ法により定量するELISAキットです。心疾患、糖尿病、脂質代謝研究などに有用です。

※本製品は研究用です。研究用以外には使用できません。

画像をクリックするとフライヤーのPDFをダウンロードできます（英語版 6ページ、351 KB）。

Proprotein convertase subtilisin/kexin type 9 (PCSK9) was first identified in 2003 and named as neural apoptosis regulated convertase 1 (NARC-1). It is the ninth member of the proprotein convertase family which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. PCSK9 is a serine protease mainly expressed in the liver and less in intestine and kidney. PCSK9 plays an important role in the regulation of serum low-density lipoprotein (LDL) cholesterol by downregulation of LDL receptor, and as such is considered a novel target in cholesterol lowering therapy. LDL cholesterol (LDL-C) binds to LDL receptors (LDLRs) on the surface of hepatic cell where the complex is internalized and transported to the endosome. LDL-C dissociates from the receptor and is catabolized whereas the LDLR is recycled to the cell surface for continued clearance of serum cholesterol. PCSK9 affects the receptor recycling pathway by binding to the LDLR and causing degradation of the receptor within the endosome/lysosome compartment. Degradation of the LDLR results in decreased clearance of serum cholesterol, and as a result a higher risk of hypercholesterolemia .Human genetic studies have shown that “gain-of-function” (GOF) mutations in the PCSK9 gene can lead to a form of familial hypercholesterolemia with a higher risk of cardiovascular disease. In contrast, humans with “loss-of-function” (LOF) mutations in the PCSK9 gene have lower serum cholesterol levels and a lower incidence of cardiovascular disease . Thus PCSK9 had a key impact not only on circulating LDL-C level but also on cardiovascular risk and atherosclerotic process.